KOL Perspectives of Adaptive Trial Designs in IBD, 2018 Study - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 22, 2019--The “KOL Perspectives: Adaptive Trial Designs in IBD” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This KOL Insight briefing focuses on KOLs views of Adaptive trial designs in IBD.
In total, we conducted interviews with 10 KOLs -
KOL data is analyzed to produce -
Reasons to Buy
Key Topics Covered:
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/x4jwc4/kol_perspectives?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190222005114/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Clinical Trials
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/22/2019 03:58 AM/DISC: 02/22/2019 03:58 AM